The Rho/SRF Pathway Inhibitor, CCG-1423, also referenced under CAS 285986-88-1, controls the biological activity of Rho/SRF. This small molecule/inhibitor is primarily used for Cell Structure applications.
別名:
Rho/SRF Pathway Inhibitor, CCG-1423, N-(2-(4-Chloroanilino)-1-methyl-2-oxoethoxy)-3,5-bis(trifluoromethyl)benzamide, MICAL-2 Inhibitor I, MRTF-A/SRF Transcription Inhibitor I, MLK1/SRF Transcription Inhibitor I
A cell-permeable benzamide compound that acts as an effective inhibitor against RhoA- and RhoC-mediated cellular activities by targeting signaling events downstream of Gα12/13 and RhoA/C, affecting MKL recruitment and/or postrecruitment function of MKL1, but not SRF-SRE interaction or ROCK kinase activity. CCG-1423 is shown to inhibit RhoC-dependent cell growth in A375M2 and SK-Mel-147 (IC50 ≤300 nM) and block RhoC/ Gα12-mediated PC-13 invasion in Matrigel assays (by ~90% at 3 µM). Shown to inhibit MICAL-2 with a Ki of 1.5 µM.
包装
Packaged under inert gas
警告
Toxicity: Standard Handling (A)
再構成
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
その他情報
Lundquist, M.R., et al. 2014. Cell156, 563.. Evelyn, C.R., et al. 2007. Mol. Cancer Ther.6, 2249.
法的情報
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Our study focused on deciphering the role of F-actin and related regulatory factors during SARS-CoV-2 particle production and transmission in human pulmonary cells. Quantitative high-resolution microscopies revealed that the late phases of SARS-CoV-2 infection induce a strong rearrangement of F-actin
Keratinocyte differentiation is an intricate process that is regulated by multiple mediators. Using cultured human keratinocytes, we found that lysophosphatidic acid (LPA) induced the differentiation of a previously unsuspected keratinocyte subpopulation expressing the extracellular matrix protein, thrombospondin-1 (THBS1). This action
